A Randomized, Post-market Study Evaluating Dermal Allograft Augmentation of Large and Massive Rotator Cuff Tears
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Full-thickness Rotator Cuff Tear
- Sponsor
- Arthrex, Inc.
- Enrollment
- 120
- Locations
- 4
- Primary Endpoint
- The primary outcome measure is healing evaluation in MRI
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
The purpose of this study is to compare postoperative healing of large and massive rotator cuff tears with preoperative MRI confirmed fatty infiltration stage II and higher repaired with or without dermal allograft augmentation (DAA).
Detailed Description
The primary objective is to evaluate postoperative healing of rotator cuff repair with and without DAA. Primary: The primary outcome measure is healing evaluation in MRI . MRI Post-Operative Assessment (Goutallier Stage and Sugaya Classification) Secondary: The secondary outcome measures are patient-reported outcome measures from validated outcome scoring systems, including: American Shoulder and Elbow Surgeons Score (ASES) Single Assessment Numeric Evaluation score (SANE) Visual Analog Scale (VAS) for pain Veterans RAND Health Survey (VR-12) Population: Males and females between the ages of 30 and 75 years that require surgery for large and massive rotator cuff tears Description of Treatment: Rotator cuff repair with or without augmentation using decellularized human dermal allograft.
Investigators
Eligibility Criteria
Inclusion Criteria
- •The subject is between the ages of 30 and 75 years.
- •Subject is planning to undergo arthroscopic surgery for full-thickness rotator cuff tear (RCT)
- •Two complete RCTs or tear size equal to or greater than 3 cm in either the anterior-posterior or medial-lateral dimension
- •Primary rotator cuff repair
- •Stage II fatty infiltration or higher of the supraspinatus or infraspinatus muscle based on preoperative MRI
- •Subject has a dual x-ray absorptiometry (DXA) or anterior posterior x-ray view of the target shoulder
Exclusion Criteria
- •The Subject is unable or unwilling to sign the patient informed consent, approved by the Institutional Review Board.
- •The subject objects to the use of allograft
- •Stage I or lower fatty infiltration of the supraspinatus AND infraspinatus muscle
- •Complete full-thickness subscapularis tears of greater than the superior one third of the tendon (Lafosse grade 3 and above)
- •Less than 2 mm joint space of the glenohumeral joint on either an anteroposterior or axillary radiograph
- •Recurrent shoulder instability
- •Corticosteroid injection in the operative shoulder within one month of surgery
- •Revision rotator cuff repair
- •Subject preoperative MRI obtained more than 12 months prior to surgery
- •Pregnant or planning to become pregnant during the study period
Outcomes
Primary Outcomes
The primary outcome measure is healing evaluation in MRI
Time Frame: 26 Weeks
MRI Post-Operative Assessment (Goutallier Stage and Sugaya Classification) MRI Post-Operative Assessment (Goutallier Stage and Sugaya Classification)
Secondary Outcomes
- The secondary outcome measures are patient-reported outcome measures from validated outcome scoring systems(Preop, 26 Weeks, 1 Year, 2 Year)
- Single Assessment Numeric Evaluation score (SANE)(Preop, 26 Weeks, 1 Year, 2 Year)
- Veterans RAND Health Survey (VR-12)(Preop, 26 Weeks, 1 Year, 2 Year)
- Visual Analog Scale (VAS) for pain(Preop, two-week, six week, 26 Weeks, 1 Year, 2 Year)